Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

Post by ChaseAcklandon Mar 02, 2021 10:34am
96 Views
Post# 32694290

Role of T-cells: these guys have it right

Role of T-cells: these guys have it rightHey Everyone,
The following 'preprint' is up on BioRxiv.  Very interesting!

https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1

The focus of i the preprint is on the critical role that CD4+ and CD8+ T cell responses play in disease resolution and modulation of COVID-19 disease severity.   Sound familiar??
There are more and more peer-reviewed pubs coming out on the role of T-cell activation in combatting SARS-CoV-2.    All you hear about in the regular media is about antibody response, antibody response, blah, blah. No doubt important to have this, but looks like BIOV has been correct from the beginning on CD4+ and CD8+ T cell responses being a game-changer.  
-Chase
<< Previous
Bullboard Posts
Next >>